rozlytrek
roche registration gmbh - entrectinib - cancer; carcinoma, non-small-cell lung - agentes antineoplásicos - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.
lumykras
amgen europe bv - sotorasib - carcinoma, pulmão de células não pequenas - agentes antineoplásicos - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.
fingolimod farmoz 0.5 mg cápsula
farmoz - sociedade técnico medicinal, s.a. - fingolimod - cápsula - 0.5 mg - fingolimod, cloridrato 0.5593 mg - fingolimod - genérico - duração do tratamento: longa duração
jaypirca
eli lilly nederland b.v. - pirtobrutinib - linfoma, mantle-cell - inibidores de proteína quinase - treatment of mantle cell lymphoma (mcl).
riximyo
sandoz do brasil indÚstria farmacÊutica ltda - rituximabe - antineoplasico
citarax
blau farmacÊutica s.a. - citarabina - antimetabolicos analogos da pirimidina
fauldcita
libbs farmacÊutica ltda - citarabina - antimetabolicos analogos da pirimidina
prelone
achÉ laboratÓrios farmacÊuticos s.a - fosfato sÓdico de prednisolona, prednisolona - glicocorticoides sistemicos
vivaxxia
libbs farmacÊutica ltda - rituximabe - antineoplasico
predsigma
nova quimica farmacÊutica s/a - fosfato sÓdico de prednisolona, prednisolona - glicocorticoides sistemicos